Companies › Kodiak Sciences
3 active drug programs in 5 registered trials: 5 Phase 3; Ophthalmology, Immunology; next expected readout Feb 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| KSI-101 IL-6 receptor antagonist (IL-6R-Fc fusion protein) | IL6R | Phase 3 | Macular Edema Secondary to Inflammation | Feb 2027 |
| Tabirafusp tedromer | – | Phase 3 | Wet Age-related Macular Degeneration; Diabetic Macular Edema (DME) | Aug 2027 |
| Tarcocimab tedromer Monoclonal antibody against complement factor C3 | C3 | Phase 3 | Wet Age-related Macular Degeneration | Aug 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06996080 | KSI-101 | Phase 3 | Macular Edema Secondary to Inflammation | Immunology | Feb 2027 |
| NCT06990399 | KSI-101 | Phase 3 | Macular Edema Secondary to Inflammation | Immunology | Apr 2027 |
| NCT06556368 | Tarcocimab tedromer | Phase 3 | Wet Age-related Macular Degeneration | Ophthalmology | Aug 2027 |
| NCT06556368 | Tabirafusp tedromer | Phase 3 | Wet Age-related Macular Degeneration | Ophthalmology | Aug 2027 |
| NCT07734844 | Tabirafusp tedromer | Phase 3 | Diabetic Macular Edema (DME) | Ophthalmology | Aug 2028 |
Cash of $126m on 2026-06-30; operating cash outflow about $175m a year; runway about 9 months at that burn, to Mar 2027; 1 of 4 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 7 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
EyePoint Pharmaceuticals Santen Pharmaceutical Annexon Alcon Research SpyGlass Pharma
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.